Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Pacini
F
F
Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, University of Siena, Italy.
Castagna
M G
MG
Brilli
L
L
Pentheroudakis
G
G
D000293:Adolescent; D001707:Biopsy, Needle; D002116:Calcitonin / Q000097:blood; D002648:Child; D005060:Europe / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D009362:Neoplasm Metastasis / Q000628:therapy; D009367:Neoplasm Staging; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction; D018570:Risk Assessment; D013960:Thyroid Function Tests; D013964:Thyroid Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D013965:Thyroidectomy; D013972:Thyrotropin / Q000009:adverse effects / Q000627:therapeutic use; D013974:Thyroxine / Q000627:therapeutic use; D016896:Treatment Outcome
D011994:Recombinant Proteins; D013972:Thyrotropin; D002116:Calcitonin; D011505:Protein-Tyrosine Kinases; D013974:Thyroxine